C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $9.33 Consensus Target Price from Analysts
C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has been given an average recommendation of “Hold” by the eight analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have issued a buy recommendation on the company. […]
More Stories
Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Aviso Wealth Management
Aviso Wealth Management grew its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 16.7% in the 3rd...
Jackson Hill Advisors LLC Cuts Stock Holdings in Alphabet Inc. (NASDAQ:GOOG)
Jackson Hill Advisors LLC lowered its position in Alphabet Inc. (NASDAQ:GOOG – Free Report) by 53.6% in the 3rd quarter,...
Capital City Trust Co. FL Acquires 1,631 Shares of Walmart Inc. (NYSE:WMT)
Capital City Trust Co. FL increased its holdings in shares of Walmart Inc. (NYSE:WMT – Free Report) by 2.0% in...
Cassaday & Co Wealth Management LLC Buys 748 Shares of Walmart Inc. (NYSE:WMT)
Cassaday & Co Wealth Management LLC raised its holdings in Walmart Inc. (NYSE:WMT – Free Report) by 3.0% during the...
Taurus Asset Management LLC Trims Stake in Bank of America Co. (NYSE:BAC)
Taurus Asset Management LLC lessened its position in Bank of America Co. (NYSE:BAC) by 4.6% in the third quarter, according...
OneAscent Wealth Management LLC Takes $647,000 Position in The Procter & Gamble Company (NYSE:PG)
OneAscent Wealth Management LLC purchased a new position in The Procter & Gamble Company (NYSE:PG – Free Report) during the...